Boston Therapeutics, Inc. Secures DTC Eligibility

MANCHESTER, NH--(Marketwire - June 07, 2012) -

Boston Therapeutics, Inc. (OTCQB: BTHE) (OTCBB: BTHE) (“Boston Therapeutics” or “the Company”), a developer of complex carbohydrates to treat diabetes and other inflammatory diseases, today announced it has secured eligibility by The Depository Trust Company (DTC) for its shares on the OTC, effective June 6, 2012. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.

“DTC eligibility simplifies the process of trading our stock,” said David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, Inc. “We expect our new status to improve market liquidity and make our stock more attractive to investors.”

The DTC is focused on creating liquidity and stability in the global capital markets by providing electronic clearance and settlement of equity trades. Having access to DTC services gives the Company greater exposure to the capital markets while at the same time offers various services including greater transparency of the Company’s shares. The DTC is a subsidiary of the Depository Trust & Clearing Corporation (DTCC), and manages the electronic clearing and settlement of publicly traded company stocks and other securities.

About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, is a leader in the field of complex carbohydrates, a specialized field involving understanding the importance of the role that carbohydrates play in biochemistry and progression of diseases. The Company’s initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement designed to moderate post-meal blood glucose, and IPOXYN™, a systemic, injectable complex carbohydrate-based oxygen therapeutic for limb ischemia. The Company petitioned the U.S. FDA to submit an Abbreviated New Drug Application (ANDA) for PAZAMET™, a chewable anti-diabetic drug. The Company signed a licensing agreement with Hong Kong-based Advance Pharmaceuticals Co. Ltd. to distribute SUGARDOWN® in Hong Kong, China and Macau. The Company also received its first commercial purchase order from a distributor in Italy to market SUGARDOWN®. In 2011, the Company completed a Phase l clinical trial with SUGARDOWN®. The Company is completing a Phase ll clinical trial for PAZ320 at Dartmouth-Hitchcock Medical Center in Hanover, NH.

Forward Looking Statements
The Company’s views as of the date of this press release should not be relied upon to represent the Company’s views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company’s views to change, the Company disclaims any obligation to update such forward-looking statements.

More information about those risks and uncertainties is contained and discussed in the Company’s most recent quarterly or annual report and in the Company’s other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company’s views as of the date of this press release and should not be relied upon to represent the Company’s views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company’s views to change, the Company disclaims any obligation to update such forward-looking statements.